Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GC-rich sequence DNA-binding factor 2 is a protein encoded by the human GCFC2 gene. Early research mistakenly identified it as a transcription factor involved in binding GC-rich DNA, based on an artificial chimera transcript. Later analyses refined its function, showing it is involved in the regulation of pre-mRNA splicing, specifically the spliceosome C complex, and may participate in turnover of excised introns. It has limited clinical association, mainly with dyslexia and reading disorders, but is not currently considered a druggable or therapeutic target. The initial molecular annotation is recognized as contentious, and its canonical function should be considered related to RNA processing rather than DNA transcription regulation. The name and historical functional annotation ("GC-rich sequence DNA-binding factor 2" as a DNA-binding transcription factor) are misleading. The actual primary function supported by current molecular data is RNA splicing regulation, not DNA binding or transcription factor activity.
None applicable, as no drugs target this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GC-rich sequence DNA-binding factor 2 (GCFC2).